Characterization of a hyaluronic acid-based hydrogel containing an extracellular oxygen carrier (M101) for periodontitis treatment: An in vitro study

Hayriye Özçelik,Fareeha Batool,Maïwenn Corre,Alexandre Garlaschelli,Guillaume Conzatti,Céline Stutz,Catherine Petit,Eric Delpy,Franck Zal,Elisabeth Leize-Zal,Olivier Huck
DOI: https://doi.org/10.1016/j.ijpharm.2021.120810
IF: 6.51
2021-08-01
International Journal of Pharmaceutics
Abstract:<p>Periodontitis is an inflammatory disease associated with anaerobic bacteria leading to the destruction of tooth-supporting tissues. <em>Porphyromonas gingivalis</em> is a keystone anaerobic pathogen involved in the development of severe lesions. Periodontal treatment aims to suppress subgingival biofilms and to restore tissue homeostasis. However, hypoxia impairs wound healing and promotes bacterial growth within periodontal pocket. This study aimed to evaluate the potential of local oxygen delivery through the local application of a hydrogel containing <em>Arenicola marina</em>'s hemoglobin (M101). To this end, a hydrogel (xanthan (2%), hyaluronic acid (1%)) containing M101 (1-2 g/mL) (Xn(2%)-HA(1%)-M101) was prepared and characterized. Rheological tests revealed the occurrence of high deformation without the loss of elastic properties. Dialysis experiment revealed that incorporation of M101 within the gel did not modify its oxygen transportation properties. Samples of release media of the gels (1g/L (10%) and 2g/L (10%) M101) decreased significantly the growth of <em>P.gingivalis</em> after 24h validating its antibacterial effect. Metabolic activity measurement confirmed the cytocompatibility of Xn(2%)-HA(1%)-M101. This study suggests the therapeutic interest of Xn(2%)-HA(1%)-M101 gel to optimize treatment of periodontitis with a non-invasive approach.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?